Tirzepatide Arrived Warm? What to Do Before Injecting

If injectable tirzepatide arrives warm or without adequate refrigeration, do not inject it while trying to decide whether it is still usable. FDA recommends not using injectable GLP-1 medication that arrives warm or with insufficient refrigeration because storage problems can affect product quality.¹

Contact the dispensing pharmacy and the service that arranged delivery. Explain the delivery time, how the medicine and packaging arrived, and whether you can establish the temperature history. A refund policy and a pharmacist’s quality assessment are separate questions.

Start with the actual medicine

Photograph the outer package, insulation, ice packs, medicine packaging and prescription label. Keep the order number and delivery notifications. These records help the pharmacy investigate the shipment and identify the exact formulation and presentation. A picture cannot establish potency, but it can preserve information that would otherwise be lost when packaging is discarded.

Say whether the medication itself felt warm, whether refrigeration was inadequate, and whether the package was damaged. Avoid reducing the report to “the ice melted.” What happened to an ice pack does not, by itself, provide a complete temperature record for the drug.

Why a room-temperature allowance does not settle it

Approved tirzepatide products have presentation-specific storage instructions. A permitted period outside the refrigerator does not tell you how hot a delivery vehicle became, how long the shipment spent at that temperature, or whether it had already used part of its allowed storage time. Nor does an instruction for an approved single-dose pen establish the stability of a different compounded formulation.²

Our storage guide distinguishes presentations. Use the instructions for your exact medication, not a screenshot of another person’s label. Do not restart a storage clock by cooling a questionable shipment and assume the problem has been reversed.

A clear vial is not a temperature certificate

Inspecting medicine before use remains important. The approved Zepbound label says not to use medicine with particles or discoloration. But a normal appearance is not proof that every storage requirement was met.²

Similarly, a sealed package does not prove an authentic pharmacy prepared the medicine. FDA has identified fraudulent compounded products carrying misleading pharmacy information. If the label is unfamiliar or inconsistent, verify it directly with the dispensing pharmacy using independently confirmed contact information.¹

What to ask the pharmacy

Request a written answer about whether the shipment meets the product’s handling requirements and whether a replacement will be supplied. Ask what to do with the questionable medicine while the issue is investigated and how to dispose of it if it cannot be used. Keep the answer with your delivery records.

For a compounded prescription, ask which pharmacy prepared it and what formulation was dispensed. The telehealth company taking payment may not be the pharmacy responsible for that assessment. Our care-options guide explains the different roles.

If the delay affects injection day

Do not inject a questionable dose simply to stay on schedule, and do not combine doses to compensate for a delayed replacement. Contact your prescriber or pharmacist about the timing. The approved missed-dose rules are explained in our missed-dose guide; they are not instructions to use medicine whose quality is uncertain.

If you already used the shipment, report the quality concern and any symptoms promptly. Seek urgent medical help for severe symptoms. FDA’s MedWatch pathway also accepts product-quality and adverse-event reports.¹